Radiopharm Theranostics (ASX:RAD) Research & Development: A$27.52 Mil (TTM As of Jun. 2025)


What is Radiopharm Theranostics Research & Development?

Radiopharm Theranostics ASX:RAD -5.00% Research & Development is A$27.52 Mil as of Jun. 2025. The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Radiopharm Theranostics's Research & Development for the six months ended in Jun. 2025 was A$13.92 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2025 was A$27.52 Mil.

Radiopharm Theranostics  (ASX:RAD) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Radiopharm Theranostics Research & Development Related Terms

Radiopharm Theranostics Research & Development Historical Data

* Premium members only.

The historical data trend for Radiopharm Theranostics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Radiopharm Theranostics Research & Development Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Research & Development
4.13 22.63 23.09 27.52

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Research & Development Get a 7-Day Free Trial 13.20 15.10 7.99 13.59 13.92

Radiopharm Theranostics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$27.52 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of A$27.52 Mil mean?
Radiopharm Theranostics (ASX:RAD) has a Research & Development of A$27.52 Mil as of Jun. 2025. Research and development expense is the total cost for research and development activities. View historical data on Radiopharm Theranostics and its competitors.
Is Radiopharm Theranostics' Research & Development too high?
Radiopharm Theranostics' current Research & Development is A$27.52 Mil.
How does Radiopharm Theranostics' Research & Development compare to VRTX and REGN?
Radiopharm Theranostics' Research & Development of A$27.52 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Radiopharm Theranostics and its competitors. Radiopharm Theranostics's current Research & Development is A$27.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radiopharm Theranostics stock overvalued right now?
Radiopharm Theranostics (ASX:RAD) has a current Research & Development of A$27.52 Mil. The current Research & Development is A$27.52 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Radiopharm Theranostics (ASX:RAD), the current Research & Development is A$27.52 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Radiopharm Theranostics Business Description

Other Exchanges RADX:USA
Address 62 Lygon Street, Suite 1, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.